Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The use of radiomics and artificial intelligence for sickle cell disease

Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy, shares some insights into the use of radiomics and artificial intelligence for sickle cell disease (SCD) and the GENOMED4ALL European project. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Transcript (edited for clarity)

On behalf of the consortium and the GENOMED4ALL radiomics use case in sickle cell disease, we are presenting an oral abstract regarding the first analysis of the radiomics sickle cell disease part. And first of all, I’d like to say that the GENOMED4ALL is an EU funded project involving 23 centers in Europe. And the fascinating thing is that involves hematologists, neuroradiologists, and artificial intelligence experts and bioinformatics...

On behalf of the consortium and the GENOMED4ALL radiomics use case in sickle cell disease, we are presenting an oral abstract regarding the first analysis of the radiomics sickle cell disease part. And first of all, I’d like to say that the GENOMED4ALL is an EU funded project involving 23 centers in Europe. And the fascinating thing is that involves hematologists, neuroradiologists, and artificial intelligence experts and bioinformatics. So it groups together different expertises.

And the entire title is genomics and personalized medicine for all through artificial intelligence in hematological disorders. So it’s a long title, but what we aim at is joining forces in different specialties to achieve a personalized medicine in multiple myeloma, myelodysplastic syndromes, and sickle cell disease, which is the only benign disease included in the consortium. But we believe we can have some common grounds that can build technologies for the non-malignant and the malignant diseases.

Read more...